GLUE MONTE ROSA THERAPEUTICS INC

Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference

Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference

BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 12:50 p.m. EDT.

A webcast of the fireside chat will be accessible via the “Events & Presentations” section of Monte Rosa’s website at , and an archived version will be made available for 30 days following the presentation.

About Monte Rosa

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans autoimmune and inflammatory diseases, oncology, and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit .

Investors

Andrew Funderburk

Media

Cory Tromblee, Scient PR



EN
28/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MONTE ROSA THERAPEUTICS INC

 PRESS RELEASE

Monte Rosa Therapeutics Announces FDA Clearance of IND Application for...

Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases MRT-8102, a highly selective NEK7-directed molecular glue degrader (MGD) developed to treat inflammatory conditions linked to NLRP3, IL-1β, and IL-6 dysregulation, expands Monte Rosa’s clinical I&I portfolio Potency, selectivity, and long-lasting pharmacodynamics of MRT-8102 observed in preclinical studies create potential for clinical differentiation from competitive approaches for inflammatory diseases MRT-8102 Phase...

 PRESS RELEASE

Monte Rosa Therapeutics to Participate in the Jefferies Global Healthc...

Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 12:50 p.m. EDT. A webcast of the fireside chat will be accessible via the “Events & Presentations” section of Monte Rosa’s website at , and an archived version will be...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch